This week peHUB is highlighting a handful of positions based in Boston, San Diego, New York and London.

NanoString Technologies, a provider of life science tools for translational research and developer of molecular diagnostic products, has completed a $15.3 million Series E Preferred Stock issuance. New investors in the transaction included Morgan Stanley Expansion Capital and AllianceBernstein Alternative Investment Management Group. All previous venture investors participated including Clarus Ventures, Draper Fisher Jurvetson, OVP Venture Partners, GE healthymagination Fund, BioMed Ventures, and Henri Termeer.

NanoString Technologies, a provider of life science tools and developer of molecular diagnostics, has appointed James A. Johnson as the company’s new chief financial officer. Johnson assumes this role from Wayne Burns who will remain with the company in his new position as senior vice president, operations and administration. NanoString Technologies is backed by GE, BioMed Ventures, Clarus Ventures, Draper Fisher Jurvetson and OVP Venture Partners.

Waltham, Mass.-based regenerative medicine developer Histogenics Corp. wrapped up a $49 million Series A round, the company revealed Tuesday. Sofinnova Ventures led the big round, and was joined by a litany of backers: Split Rock Partners, BioMed Ventures and FinTech GIMV Fund, L.P. invested for the first time, and were joined by ProChon Holdings BV, [...]